{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:00:16Z","timestamp":1762376416090},"reference-count":20,"publisher":"SLACK, Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pediatr Ophthalmol Strabismus"],"published-print":{"date-parts":[[2018,9,20]]},"abstract":"\n Purpose:<\/jats:title>\n To evaluate the response to corticosteroid therapy as a primary treatment for ocular myasthenia gravis.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Patients diagnosed as having ocular myasthenia gravis by an acetylcholine receptor binding antibody test between January 2011 and September 2015 were included in the study and started receiving treatment with a corticosteroid. Patients with a blowout fracture, hyperthyroidism, diabetes mellitus, hypertension, cardiovascular disease, or history of strabismus surgery were excluded. Disappearance of diplopia and ptosis were considered a response to treatment.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Methylprednisolone therapy was administered to 29 patients (19 men and 10 women; average age: 49 \u00b1 16.5 years) as an initial treatment. A total of 6 patients were lost to follow-up. Twenty-three of 29 patients (82.6%) were regarded as having presented a response to treatment. The average treatment duration was 3 weeks for patients responding to primary treatment. Eight patients complained of adverse effects from steroid therapy such as heartburn, insomnia, weight gain, and myalgia.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n A corticosteroid could be considered as an initial treatment for patients diagnosed as having ocular myasthenia gravis by an acetylcholine receptor binding antibody test.<\/jats:p>\n \n \n [\n J Pediatr Ophthalmol Strabismus<\/jats:italic>\n . 2018;55(5):339-342.]\n <\/jats:bold>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3928\/01913913-20180620-01","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T12:44:45Z","timestamp":1533300285000},"page":"339-342","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and Safety of Low-to-Moderate Dose Oral Corticosteroid Treatment in Ocular Myasthenia Gravis"],"prefix":"10.3928","volume":"55","author":[{"given":"Yoon Gon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ungsoo Samuel","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ohc.2004.05.014"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200115060-00003"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1998.tb05968.x"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb22937.x"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1996.00550080128020"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.2.243"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12057"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e328358b94a"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12261"},{"key":"e_1_3_1_12_2","first-page":"681","article-title":"Ocular myasthenia gravis","volume":"85","author":"March GA","year":"1993","unstructured":"March GA, Johnson LN. Ocular myasthenia gravis. J Natl Med Assoc. 1993;85:681\u2013684.","journal-title":"J Natl Med Assoc"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70063-8"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24438"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197401102900204"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.24769"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e328310da18"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1988.tb06970.x"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-8966(00)00173-5"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51325.x"},{"key":"e_1_3_1_21_2","first-page":"1117","article-title":"Clinical profiles of Thai patients with ocular myasthenia gravis in Siriraj Hospital","volume":"94","author":"Leeamornsiri S","year":"2011","unstructured":"Leeamornsiri S, Chirapapaisan N, Chuenkongkaew W. Clinical profiles of Thai patients with ocular myasthenia gravis in Siriraj Hospital. J Med Assoc Thai. 2011;94:1117\u20131121.","journal-title":"J Med Assoc Thai"}],"container-title":["Journal of Pediatric Ophthalmology & Strabismus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.healio.com\/doiresolver?doi=10.3928\/01913913-20180620-01","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T11:28:02Z","timestamp":1683113282000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/01913913-20180620-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9,20]]}},"alternative-id":["10.3928\/01913913-20180620-01"],"URL":"https:\/\/doi.org\/10.3928\/01913913-20180620-01","relation":{},"ISSN":["0191-3913","1938-2405"],"issn-type":[{"value":"0191-3913","type":"print"},{"value":"1938-2405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]}}}